Clindamycin Phosphate

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

42 API Suppliers, 18 USDMF, 13 CEP/COS, 6 JDMF, 1 EU WC, 2 KDMF, 14 NDC API, 19 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

25 Drugs in Development

25 Drugs in Development

INTERMEDIATES

1 Intermediate Suppliers

1 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

240 FDF Dossiers, 134 FDA Orange Book, 79 Europe, 16 Canada, 1 South Africa, 10 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

SOLUTION;INTRAVENOUS - EQ 300MG BASE/50ML (EQ 6MG BASE/ML), SOLUTION;INTRAVENOUS - EQ 600MG BASE/50ML (EQ 12MG BASE/ML), SOLUTION;INTRAVENOUS - EQ 900MG BASE/50ML (EQ 18MG BASE/ML), INJECTABLE;INJECTION - EQ 150MG BASE/ML, SOLUTION;TOPICAL - EQ 1% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, LOTION;TOPICAL - EQ 1% BASE, GEL;TOPICAL - EQ 1% BASE, GEL;TOPICAL - 5%;1.2%, GEL;TOPICAL - 5%;EQ 1% BASE, SUPPOSITORY;VAGINAL - 100MG, GEL;TOPICAL - EQ 1% BASE, CREAM;VAGINAL - EQ 2% BASE, AEROSOL, FOAM;TOPICAL - 1% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, GEL;TOPICAL - 1.2%;0.025%

RELATED EXCIPIENT COMPANIES

2 EUROAPI, 2 Rochem International Inc, 3 SPI Pharma, 5 DKSH, 1 Pharm-RX Chemical, 1 Gangwal Healthcare, 10 Nanjing Well Pharmaceutical, 1 Pfanstiehl, 6 Kirsch Pharma, 8 Actylis, 1 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 13 BASF, 1 BioSpectra, 2 CD Formulation, 1 Clariant, 6 Corel Pharma Chem, 1 Esteem Industries, 2 Finar, 7 Gangwal Chemicals, 1 Kerry, 5 Lubrizol Life Science Health, 4 Microlex e.U, 1 Nanjing Bold Chemical, 2 Pluviaendo, 16 Roquette, 10 Seppic, 1 Shijiazhuang Huaxu Pharmaceutical, 1 Sigachi Industries, 1 Valens Pharmachem, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

38 Topical, 27 Thickeners and Stabilizers, 27 Parenteral, 25 Solubilizers, 16 Emulsifying Agents, 16 Film Formers & Plasticizers, 13 Fillers, Diluents & Binders, 9 Surfactant & Foaming Agents, 7 Direct Compression, 7 Controlled & Modified Release, 7 Rheology Modifiers, 7 Coating Systems & Additives, 6 Lubricants & Glidants, 5 Taste Masking, 4 Granulation, 3 Chewable & Orodispersible Aids, 3 Co-Processed Excipients, 3 API Stability Enhancers, 1 Soft Gelatin

DIGITAL CONTENT

2 Data Compilation #PharmaFlow, 57 News #PharmaBuzz

GLOBAL SALES INFORMATION

29 US Medicaid Prescriptions, 8 Regulatory FDF Prices

MARKET PLACE

33 APIs, 4 FDF Dossiers

PATENTS & EXCLUSIVITIES

22 US Patents, 2 US Exclusivities, 3 Health Canada Patents

REF. STANDARDS & IMPURITIES

3 EDQM, 1 USP, 2 Others

$ Xls

Filters

Xls

USFDA APPLICATION NUMBER - 208083 / DOSAGE - SOLUTION;INTRAVENOUS - EQ 300MG BASE/50ML (EQ 6MG BASE/ML)

Ingredient Name	Basis of Strength	Strength
Active Ingredient/Active Moiety
CLINDAMYCIN PHOSPHATE(UNII: EH6D7113I8) (CLINDAMYCIN - UNII:3U02EL437C)	CLINDAMYCIN PHOSPHATE	300mg in 50 \| 600mg in 50 \| 900mg in 50

Inactive Ingredients

Ingredient Name	Baxter Healthcare Corporation
EDETATE DISODIUM(7FLD91C86K)
HYDROCHLORIC ACID(QTT17582CB)
SODIUM CHLORIDE(451W47IQ8X)
SODIUM HYDROXIDE(55X04QC32I)
WATER(059QF0KO0R)

Drug Product Composition: Clindamycin Phosphate